Analyst Ratings for Editas Medicine (EDIT)
EDIT Rating Summary
EDIT Price Target Summary
- Highest: $20.00 (Truist Securities)
- Lowest: $8.00 (RBC Capital)
- Average: $14.00
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$14.00 (+161.7%)
* Over Last 12-Mos
Rating Score: 4.6 / 10
Percentile Rank: 47%
Avg. $ Target:
$14.00 (+161.7%)
* Over Last 12-Mos
Rating Score: 4.6 / 10
Percentile Rank: 47%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/24/2023 | Citi » Updated 2/28/2024 |
Samantha Semenkow | Upgrade | Buy (Neutral) |
16.00 (11.00) |
6.25 (5.35) |
-14.4% | Details |
| 10/18/2023 | JPMorgan » Updated 2/27/2024 |
Brian Cheng | Upgrade | Neutral (Underweight) |
9.00 (8.00) |
6.81 (5.35) |
-21.44% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
